Non-Hodgkin Lymphoma — Trials

Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

8,119 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,168
Recruiting: 1,128
Ph III recruiting: 115
Growth YoY: +8.3%
Industry share: 27%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.5%
Trials / 1,000 deaths: 108.5 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,288)

clinicaltrialsPublishedShowing 101–103 of 103 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04934475	MInimal Residual Disease Adapted Strategy(MIDAS)	active not recruiting	Phase 3	791	Intergroupe Francophone du MyelomeNETWORK	3	Nov 7, 2024	clinicaltrials
NCT03948035	Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM	active not recruiting	Phase 3	576	Wuerzburg University HospitalOTHER	2	May 6, 2023	clinicaltrials